about
Diminished orientation-specific surround suppression of visual processing in schizophreniaThe effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.Increased prolactin levels are associated with impaired processing speed in subjects with early psychosisSchizophrenia: redox regulation and volume neurotransmissionCognitive control deficits in schizophrenia: mechanisms and meaningEmotional memory in schizophrenia.Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysisEffect of second-generation antipsychotics on cognition: current issues and future challenges.Informed consent to research in persons with schizophrenia spectrum disorders.Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosisDisorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognitionNew targets in the treatment of anorexia nervosa.The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial.Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia.Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.What do we know about neuropsychological aspects of schizophrenia?Neuronal glucose metabolism and schizophrenia: therapeutic prospects?Prevention of schizophrenia.Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.The quest for developing new treatments from imaging techniques: promises, problems and future potential.A few methodologic issues of note.Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia.Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.Antipsychotics decrease response confidence.Examining informed consent in persons with schizophrenia
P2860
Q24652714-03A8A958-A9F9-42A8-B1CB-D6DF84022EE6Q25256710-EE877035-40F8-4C7C-ABCE-D49F71C28399Q28540093-A2786C56-0169-4C8C-8BED-6C08A2308A35Q28742799-A17613BB-C705-4BC6-A673-39D86B4312AFQ30476447-890DBAAF-9E9B-45BF-BE6C-317B3D612807Q30487303-1719A717-6938-4077-ADAC-661081878196Q30977943-0B0E5F11-4650-4014-B4FD-490655D9F3F1Q33675212-AB1FEFD8-601E-40D6-9156-7A426350C1D4Q33888153-84B04DB8-4B66-48A7-B3C3-475317A2CC0FQ34162715-77DC9AD1-7BEB-4915-A64D-E32D88828374Q34249753-BE9EF30F-1FA4-4D85-9ED6-43ADB3F89D6DQ34274859-E9DFF5DC-8E1F-4E76-BF87-C1A035A7E795Q34338202-B83D53C3-0A94-4001-8BA6-27E2C2C60308Q34604342-EA9601C0-E677-4E69-8680-BCA17D305886Q35177285-AA7CA6C5-8007-46FA-9EBD-3631CEB58B23Q35252491-4CC9887E-CF12-402F-A5B2-F9EE606D50FCQ36066305-AB2FC7A0-5F3E-4008-8D37-703588FC1767Q36262544-7FBB8A8F-C052-47C0-ACED-9EF06BE075F1Q36823176-8BFA2151-E6E5-4767-979D-2F1554BFE048Q36858373-D5B26750-CDAE-4DB9-901E-2DA86175B957Q37100402-4BB78B60-50F6-42D9-BBCD-4CDED2E9D91CQ37224949-C82C4041-F55B-486D-A551-0A58DED2BADCQ37310164-E2021344-F7B3-4E0E-A32D-31F469D8AA9EQ37350409-32595AFD-3D8D-440F-BFE1-6BA2A630B858Q37610162-6DFB0D5C-B484-4301-85FA-9B3120149A1FQ37768447-0C353F5E-9D07-442B-ACB5-D7ADED4E220EQ38403090-5F17467D-4CF0-44C6-9383-DE2CB41C7C93Q40188554-A5BD33C1-E1E8-4871-9A73-CFC0E4DD2CF0Q43191997-3679FF6F-CAD2-468E-AC75-66839FD417B4Q44473781-5F771655-0BB0-4F67-BABF-6EAB2F53F5D8Q44539672-9DF5A9F6-3EA5-4A4C-A499-6DE44CD29FBBQ45172279-36D5DDF2-7791-4E9E-B0E6-839FFB963C6FQ45899470-46F94514-D85B-4FDE-950D-71C49CE3D4BCQ45975074-7C0EC3C6-657B-4A15-8E88-82D01535F768Q52673198-3287B3C8-B2EF-4AC7-93FC-66D37D6B8243Q53092564-5B4DE768-287C-4687-9005-C70640459D2BQ56784935-7A9D3E89-3B31-4E5D-A924-A7D5AADA8D7B
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Another view of therapy for cognition in schizophrenia.
@en
Another view of therapy for cognition in schizophrenia.
@nl
type
label
Another view of therapy for cognition in schizophrenia.
@en
Another view of therapy for cognition in schizophrenia.
@nl
prefLabel
Another view of therapy for cognition in schizophrenia.
@en
Another view of therapy for cognition in schizophrenia.
@nl
P1476
Another view of therapy for cognition in schizophrenia.
@en
P2093
James M Gold
William T Carpenter
P304
P356
10.1016/S0006-3223(02)01399-9
P407
P577
2002-06-01T00:00:00Z